Rep. Lisa C. McClain Sells Kenvue Inc. (NYSE:KVUE) Stock

Representative Lisa C. McClain (R-Michigan) recently sold shares of Kenvue Inc. (NYSE:KVUE). In a filing disclosed on November 21st, the Representative disclosed that they had sold between $1,001 and $15,000 in Kenvue stock on October 31st. The trade occurred in the Representative’s “CHARLES SCHWAB 401K > SCHWAB 893” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Coherent (NYSE:COHR) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Clorox (NYSE:CLX) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Northern Trust (NASDAQ:NTRS) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Honda Motor (NYSE:HMC) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Home BancShares (NYSE:HOMB) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Five Below (NASDAQ:FIVE) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Pure Storage (NYSE:PSTG) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 10/31/2025.

Kenvue Price Performance

Shares of NYSE:KVUE traded up $0.19 during midday trading on Wednesday, hitting $17.22. The stock had a trading volume of 46,258,897 shares, compared to its average volume of 24,096,510. The company’s 50-day moving average price is $16.12 and its 200-day moving average price is $19.67. Kenvue Inc. has a fifty-two week low of $14.02 and a fifty-two week high of $25.17. The company has a quick ratio of 0.69, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $32.98 billion, a P/E ratio of 22.95 and a beta of 0.71.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Monday, November 3rd. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. The business had revenue of $3.76 billion for the quarter, compared to analysts’ expectations of $3.83 billion. Kenvue had a net margin of 9.55% and a return on equity of 20.02%. The firm’s quarterly revenue was down 3.5% compared to the same quarter last year. During the same period last year, the firm posted $0.28 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, equities research analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, November 26th. Shareholders of record on Wednesday, November 12th will be issued a $0.2075 dividend. This represents a $0.83 annualized dividend and a yield of 4.8%. The ex-dividend date of this dividend is Wednesday, November 12th. Kenvue’s dividend payout ratio (DPR) is currently 110.67%.

Analyst Ratings Changes

KVUE has been the subject of several recent analyst reports. Rothschild & Co Redburn upgraded Kenvue from a “neutral” rating to a “buy” rating and dropped their price objective for the stock from $22.50 to $22.00 in a research report on Friday, September 26th. Deutsche Bank Aktiengesellschaft set a $18.00 target price on shares of Kenvue in a report on Friday, October 24th. Zacks Research raised shares of Kenvue to a “strong sell” rating in a report on Monday, August 11th. Barclays upped their price objective on shares of Kenvue from $17.00 to $18.00 and gave the stock an “equal weight” rating in a research report on Monday, November 10th. Finally, Bank of America cut their target price on shares of Kenvue from $25.00 to $21.00 and set a “buy” rating on the stock in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $20.23.

Institutional Investors Weigh In On Kenvue

Institutional investors have recently added to or reduced their stakes in the business. Renaissance Capital LLC increased its position in shares of Kenvue by 8.3% during the second quarter. Renaissance Capital LLC now owns 629,177 shares of the company’s stock valued at $13,169,000 after buying an additional 48,267 shares during the period. Farther Finance Advisors LLC grew its stake in Kenvue by 80.7% during the second quarter. Farther Finance Advisors LLC now owns 36,196 shares of the company’s stock valued at $758,000 after acquiring an additional 16,164 shares in the last quarter. Arlington Partners LLC purchased a new position in Kenvue during the second quarter valued at approximately $2,110,000. Cornell Pochily Investment Advisors Inc. increased its holdings in Kenvue by 144.6% during the 2nd quarter. Cornell Pochily Investment Advisors Inc. now owns 33,173 shares of the company’s stock worth $694,000 after acquiring an additional 19,609 shares during the period. Finally, IFP Advisors Inc lifted its stake in Kenvue by 25.3% in the 1st quarter. IFP Advisors Inc now owns 15,278 shares of the company’s stock worth $369,000 after purchasing an additional 3,081 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.